Mike Quigley’s passion for science led him to marine biology, but his devotion for his mother took him into one of the hottest areas of cancer research: immunotherapy. At Bristol-Myers Squibb, which developed the immunotherapy drugs Yervoy and Opdivo, he is leading a Redwood City unit focused on finding out why some cancer patients who initially see positive results from immunotherapy drugs ultimately relapse. Quigley was a freshman at a small Florida college when his mother died in 2000 from metastatic melanoma.
blaineonline.finance.blog 